Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Cirrhosis

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 206 articles:
HTML format
Text format



Single Articles


    February 2017
  1. SINHA R, Lockman KA, Mallawaarachchi N, Robertson M, et al
    Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
    J Hepatol. 2017 Feb 14. pii: S0168-8278(17)30073.
    PubMed     Text format     Abstract available


  2. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    PubMed     Text format     Abstract available


    January 2017
  3. BOURSIER J, de Ledinghen V, Leroy V, Anty R, et al
    A stepwise algorithm using a at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.
    J Hepatol. 2017 Jan 11. pii: S0168-8278(17)30007.
    PubMed     Text format     Abstract available


    December 2016
  4. CRUZ-LEMINI M, Altamirano J, Ndugga N, Abraldes JG, et al
    Reply to: Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30756.
    PubMed     Text format    


  5. AYUBI E, Safiri S, Sani M, Khazaei S, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30758.
    PubMed     Text format    


  6. WEISS E, Rautou PE, Fasseu M, Giabicani M, et al
    Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30741.
    PubMed     Text format     Abstract available


  7. ARROYO V, Moreau R
    Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis.
    J Hepatol. 2016 Dec 15. pii: S0168-8278(16)30577.
    PubMed     Text format    


  8. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    PubMed     Text format     Abstract available


  9. MONTAGNESE S, De Rui M, Angeli P, Amodio P, et al
    Neuropsychiatric Performance in Patients with Cirrhosis: Who is "Normal"?
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30698.
    PubMed     Text format     Abstract available


    November 2016
  10. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Human liver regeneration in advanced cirrhosis is organized by the portal tree.
    J Hepatol. 2016 Nov 29. pii: S0168-8278(16)30690.
    PubMed     Text format     Abstract available


  11. NOTARPAOLO A, Layese R, Magistri P, Gambato M, et al
    Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    J Hepatol. 2016 Nov 26. pii: S0168-8278(16)30688.
    PubMed     Text format     Abstract available


  12. REIBERGER T, Mandorfer M
    Beta adrenergic blockade and decompensated cirrhosis.
    J Hepatol. 2016 Nov 15. pii: S0168-8278(16)30647.
    PubMed     Text format     Abstract available


    October 2016
  13. WANNHOFF A, Friedrich K, Gotthardt DN
    Reduced influence of procoagulant changes on survival in patients with advanced cirrhosis.
    J Hepatol. 2016 Oct 24. pii: S0168-8278(16)30583.
    PubMed     Text format    


  14. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    PubMed     Text format     Abstract available


  15. POTZE W, Sanyal AJ, Lisman T
    How to assess hemostatic capacity in patients with cirrhosis?
    J Hepatol. 2016 Oct 18. pii: S0168-8278(16)30576.
    PubMed     Text format    


    September 2016
  16. CHAYANUPATKUL M, Omino R, Mittal S, Kramer JR, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2016 Sep 28. pii: S0168-8278(16)30540.
    PubMed     Text format     Abstract available


  17. SHIN WJ, Song JG, Jun IG, Moon YJ, et al
    Effect of ventriculo-arterial coupling on transplant outcomes in cirrhotics: Analysis of pressure-volume curve relations.
    J Hepatol. 2016 Sep 26. pii: S0168-8278(16)30536.
    PubMed     Text format     Abstract available


    August 2016
  18. BRITO-AZEVEDO A, Perez RM, Moraes Coelho HS, Fernandes ES, et al
    The Anti-inflammatory Role of Propranolol in Cirrhosis: Preventing the Inflammatory Exhaustion?
    J Hepatol. 2016 Aug 16. pii: S0168-8278(16)30432.
    PubMed     Text format    


    July 2016
  19. CARDOSO H, Vale AM, Rodrigues S, Goncalves R, et al
    High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30397.
    PubMed     Text format    


  20. SOLA E, Kerbert JC, Verspaget HW, Moreira R, et al
    Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis.
    J Hepatol. 2016 Jul 12. pii: S0168-8278(16)30326.
    PubMed     Text format     Abstract available


  21. ALAVI M, Law MG, Grebely J, Amin J, et al
    Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012.
    J Hepatol. 2016 Jul 8. pii: S0168-8278(16)30321.
    PubMed     Text format     Abstract available


  22. STEIN E, Cruz-Lemini M, Altamirano J, Ndugga N, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide.
    J Hepatol. 2016 Jul 5. pii: S0168-8278(16)30307.
    PubMed     Text format     Abstract available


  23. CHEUNG MC, Walker AJ, Hudson BE, Verma S, et al
    Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30314.
    PubMed     Text format     Abstract available


  24. MAURICE J, Brodkin E, Arnold F, Navaratnam A, et al
    Validation of the Baveno Vi Criteria to Identify Low Risk Cirrhotic Patients not Requiring Endoscopic Surveillance for Varices.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30316.
    PubMed     Text format     Abstract available


    June 2016
  25. CONTI F, Buonfiglioli F, Scuteri A, Crespi C, et al
    Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals.
    J Hepatol. 2016 Jun 24. pii: S0168-8278(16)30303.
    PubMed     Text format     Abstract available


  26. KOZBIAL K, Moser S, Schwarzer R, Laferl H, et al
    Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment.
    J Hepatol. 2016 Jun 15. pii: S0168-8278(16)30271.
    PubMed     Text format    


  27. DAVULURI G, Krokowski D, Guan BJ, Kumar A, et al
    Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of L-leucine in cirrhosis.
    J Hepatol. 2016 Jun 15. pii: S0168-8278(16)30266.
    PubMed     Text format     Abstract available


  28. RATZIU V, Marchesini G
    When the journey from obesity to cirrhosis takes an early start.
    J Hepatol. 2016 Jun 14. pii: S0168-8278(16)30207.
    PubMed     Text format    


  29. SINCLAIR M, Grossmann M, Hoermann R, Angus PW, et al
    Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.
    J Hepatol. 2016 Jun 13. pii: S0168-8278(16)30269.
    PubMed     Text format     Abstract available


  30. KALAMBOKIS GN, Oikonomou A, Christou L, Kolaitis NI, et al
    von Willebrand factor and procoagulant imbalance independently predict outcome in patients with cirrhosis and thrombocytopenia.
    J Hepatol. 2016 Jun 10. pii: S0168-8278(16)30262.
    PubMed     Text format     Abstract available


    May 2016
  31. NADIM MK, Durand F, Kellum JA, Levitsky J, et al
    Corrigendum to "Management of the critically ill patients with cirrhosis: A multidisciplinary perspective".
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30185.
    PubMed     Text format    


  32. FRANCOZ C, Nadim MK, Durand F
    Kidney Biomarkers in Cirrhosis.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30211.
    PubMed     Text format     Abstract available


  33. OLESEN SS, Gram M, Jackson CD, Halliday E, et al
    Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy.
    J Hepatol. 2016 May 13. pii: S0168-8278(16)30189.
    PubMed     Text format     Abstract available


  34. VANDENBULCKE H, Moreno C, Colle I, Knebel JF, et al
    Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis: a prospective study.
    J Hepatol. 2016 May 12. pii: S0168-8278(16)30184.
    PubMed     Text format     Abstract available


    April 2016
  35. FOSTER G
    Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme".
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30142.
    PubMed     Text format    


  36. GRAY E, O'Leary A, Stewart S, Bergin C, et al
    High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30143.
    PubMed     Text format    


  37. MARI M, Tutusaus A, Garcia de Frutos P, Morales A, et al
    Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis.
    J Hepatol. 2016;64:983-4.
    PubMed     Text format    


  38. PETTA S, Marra F
    Reply to 'Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis'.
    J Hepatol. 2016;64:984-5.
    PubMed     Text format    


  39. DUBUQUOY L
    Lipocalin 2 highlights the complex role of neutrophils in alcoholic liver disease.
    J Hepatol. 2016;64:770-2.
    PubMed     Text format    


  40. WESTBROOK RH, Dusheiko G, Williamson C
    Pregnancy and liver disease.
    J Hepatol. 2016;64:933-45.
    PubMed     Text format     Abstract available


    March 2016
  41. BRUNO S, Di Marco V, Iavarone M, Roffi L, et al
    Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
    J Hepatol. 2016 Mar 23. pii: S0168-8278(16)00075.
    PubMed     Text format     Abstract available


  42. ARIZA X, Graupera I, Coll M, Sola E, et al
    Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis.
    J Hepatol. 2016 Mar 14. pii: S0168-8278(16)30029.
    PubMed     Text format     Abstract available


  43. CURRY MP
    DAA for decompensated cirrhosis. Efficacy and safety are now established.
    J Hepatol. 2016 Mar 3. pii: S0168-8278(16)30007.
    PubMed     Text format    


  44. PETTA S, Valenti L, Marra F, Grimaudo S, et al
    MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.
    J Hepatol. 2016;64:682-90.
    PubMed     Text format     Abstract available


  45. MOOKERJEE RP, Pavesi M, Thomsen KL, Mehta G, et al
    Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.
    J Hepatol. 2016;64:574-82.
    PubMed     Text format     Abstract available


    February 2016
  46. BUCSICS T, Schwabl P, Mandorfer M, Peck-Radosavljevic M, et al
    Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP).
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00155.
    PubMed     Text format    


  47. ALEXOPOULOU A, Vasilieva L, Agiasotelli D, Dourakis SP, et al
    Reply to "Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis".
    J Hepatol. 2016 Feb 20. pii: S0168-8278(16)00121.
    PubMed     Text format    


  48. LOUVET A
    Restoration of bactericidal activity of neutrophils by myeloperoxidase release: a new perspective for preventing infection in alcoholic cirrhosis.
    J Hepatol. 2016 Feb 13. pii: S0168-8278(16)00125.
    PubMed     Text format    


  49. ESLAM M, Hashem AM, Romero-Gomez M, Berg T, et al
    FibroGENE: A gene-based model for staging liver fibrosis.
    J Hepatol. 2016;64:390-8.
    PubMed     Text format     Abstract available


    January 2016
  50. FOSTER GR, Irving WL, Cheung MC, Walker AJ, et al
    Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jan 29. pii: S0168-8278(16)00065.
    PubMed     Text format     Abstract available


  51. TREBICKA J, von Heydebrand M, Lehmann J, Tofteng F, et al
    Assessment of beta-blocker response by expression of beta-Arrestin2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients.
    J Hepatol. 2016 Jan 28. pii: S0168-8278(16)00057.
    PubMed     Text format     Abstract available


  52. UDOMPAP P, Mannalithara A, Heo N, Kim D, et al
    Increasing Prevalence of Cirrhosis among US Adults Aware or Unaware of their Chronic Hepatitis C Virus Infection.
    J Hepatol. 2016 Jan 22. pii: S0168-8278(16)00014.
    PubMed     Text format     Abstract available


  53. LUA I, Li Y, Zagory JA, Wang KS, et al
    Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers.
    J Hepatol. 2016 Jan 19. pii: S0168-8278(16)00015.
    PubMed     Text format     Abstract available


  54. YANG YH, Chen WC, Tsai YH, Chen PC, et al
    Reply to "Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection".
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00011.
    PubMed     Text format    


  55. MCPHAIL MJ, Shawcross DL, Lewis MR, Coltart I, et al
    Multivariate metabotyping of plasma accurately predicts survival in patients with decompensated cirrhosis.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00006.
    PubMed     Text format     Abstract available


  56. FIORE M, Leone S
    Use of anti-fungals in critically ill cirrhotic patients with spontaneous peritonitis.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00013.
    PubMed     Text format    


  57. YU ML
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00012.
    PubMed     Text format    


  58. CASTERA L
    Non-invasive tests for liver fibrosis progression and regression.
    J Hepatol. 2016;64:232-3.
    PubMed     Text format    


  59. YOUNOSSI ZM, Stepanova M, Estep M, Negro F, et al
    Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    J Hepatol. 2016;64:29-36.
    PubMed     Text format     Abstract available


  60. KARSDAL MA, Genovese F, Madsen EA, Manon-Jensen T, et al
    Collagen and tissue turnover as a function of age: Implications for fibrosis.
    J Hepatol. 2016;64:103-9.
    PubMed     Text format     Abstract available


  61. JIANG M, Klein M, Zanger UM, Mohammad MK, et al
    Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease.
    J Hepatol. 2016;64:44-52.
    PubMed     Text format     Abstract available


    December 2015
  62. GARCIA-TSAO G
    Beta-Blockers in Cirrhosis: The Window Re-Opens.
    J Hepatol. 2015 Dec 24. pii: S0168-8278(15)00814.
    PubMed     Text format    


  63. UBEDA M, Lario M, Munoz L, Borrero MJ, et al
    Obeticholic acid reduces bacterial translocation, restores intestinal barrier and inhibits inflammation in cirrhotic rats.
    J Hepatol. 2015 Dec 23. pii: S0168-8278(15)00812.
    PubMed     Text format     Abstract available


  64. BOUSSIF A, Rolas L, Weiss E, Bouriche H, et al
    Impaired AKT/MAP-Kinase signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis.
    J Hepatol. 2015 Dec 21. pii: S0168-8278(15)00806.
    PubMed     Text format     Abstract available


  65. CERINI F, Vilaseca M, Lafoz E, Garcia-Irigoyen O, et al
    Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    J Hepatol. 2015 Dec 11. pii: S0168-8278(15)00804.
    PubMed     Text format     Abstract available


    November 2015
  66. KOOT BG, Alders M, Verheij J, Beuers UH, et al
    A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00785.
    PubMed     Text format     Abstract available


  67. WELKER MW, Luhne S, Lange CM, Vermehren J, et al
    Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00792.
    PubMed     Text format     Abstract available


  68. GRONBAEK H, Rodgaard-Hansen S, Aagaard NK, Arroyo V, et al
    The soluble macrophage activation markers sCD163 and Mannose Receptor (sMR) predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
    J Hepatol. 2015 Nov 27. pii: S0168-8278(15)00779.
    PubMed     Text format     Abstract available


  69. PAGE A, Paoli P, Moran Salvador E, White S, et al
    Hepatic Stellate Cell Transdifferentiation Involves Genome-Wide Remodeling of the DNA Methylation Landscape.
    J Hepatol. 2015 Nov 26. pii: S0168-8278(15)00782.
    PubMed     Text format     Abstract available


  70. RAY KIM W, Berg T, Asselah T, Flisiak R, et al
    Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00770.
    PubMed     Text format     Abstract available


  71. EGUCHI A, Jeu XM, Johnson CD, Nektaria A, et al
    Liver Bid-suppression for treatment of fibrosis associated with nonalcoholic steatohepatitis.
    J Hepatol. 2015 Nov 7. pii: S0168-8278(15)00732.
    PubMed     Text format     Abstract available


    October 2015
  72. NADIM MK, Durand F, Kellum JA, Levitsky J, et al
    Management of the Critically Ill Patient with Cirrhosis: A Multidisciplinary Perspective.
    J Hepatol. 2015 Oct 28. pii: S0168-8278(15)00718.
    PubMed     Text format    


  73. ORO D, Yudina T, Fernandez-Varo G, Casals E, et al
    Cerium oxide nanoparticles reduce steatosis, portal hypertension and display antiinflammatory properties in rats with liver fibrosis.
    J Hepatol. 2015 Oct 28. pii: S0168-8278(15)00719.
    PubMed     Text format     Abstract available


  74. FELD JJ, Moreno C, Trinh R, Tam E, et al
    Sustained Virologic Response of 100% in HCV Genotype 1b Patients with Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir for 12 Weeks.
    J Hepatol. 2015 Oct 14. pii: S0168-8278(15)00676.
    PubMed     Text format     Abstract available


  75. CHUNG SI, Moon H, Ju HL, Cho KJ, et al
    Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model.
    J Hepatol. 2015 Oct 12. pii: S0168-8278(15)00678.
    PubMed     Text format     Abstract available


    September 2015
  76. BEUERS U, Gershwin ME, Gish RG, Invernizzi P, et al
    Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.
    J Hepatol. 2015 Sep 10. pii: S0168-8278(15)00459.
    PubMed     Text format    


  77. GALBOIS A, Maury E, Guidet B, Ait-Oufella H, et al
    Reply to: "Is skin mottling a predictor of high mortality in non-selected patients with cirrhosis admitted to intensive care unit?".
    J Hepatol. 2015;63:772-3.
    PubMed     Text format    


  78. CASSINOTTO C, de Ledinghen V
    Reply to: "New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?".
    J Hepatol. 2015;63:767.
    PubMed     Text format    


  79. LANTHIER N, Starkel P, Horsmans Y
    New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?
    J Hepatol. 2015;63:765-6.
    PubMed     Text format    


    August 2015
  80. MORATALLA A, Caparros E, Juanola O, Portune K, et al
    Bifidobacterium pseudocatenulatum CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00592.
    PubMed     Text format     Abstract available


  81. BUREAU C, Laurent J, Robic MA, Christol C, et al
    Central obesity is associated with non-cirrhotic portal-vein thrombosis.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00596.
    PubMed     Text format     Abstract available


  82. LEI XF, Fu W, Kim-Kaneyama JR, Omoto T, et al
    Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00598.
    PubMed     Text format     Abstract available


  83. KAMATH PS, Poterucha JJ, Ludwig J
    Primary Biliary Cirrhosis by Another Name is Still PBC.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00555.
    PubMed     Text format    


  84. GRANCINI V, Trombetta M, Lunati ME, Zimbalatti D, et al
    Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00553.
    PubMed     Text format     Abstract available


  85. BOSCH A, Dumortier J, Maucort-Boulch D, Scoazec JY, et al
    Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.
    J Hepatol. 2015 Aug 14. pii: S0168-8278(15)00545.
    PubMed     Text format     Abstract available


    July 2015
  86. TODD STRAVITZ R, Reuben A, Mizrahi M, Lalazar G, et al
    Use of the Methacetin Breath Test to Classify the Risk of Cirrhotic Complications and Mortality in Patients Evaluated/Listed for Liver Transplantation.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00512.
    PubMed     Text format     Abstract available


  87. ZHENG Z, Zhang X, Wang J, Dandeka A, et al
    Exposure to Fine Airborne Particulate Matters Induces Hepatic Fibrosis in Murine Models.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00511.
    PubMed     Text format     Abstract available


  88. EL-SHAMY A, Eng FJ, Doyle EH, Klepper AL, et al
    A Cell Culture System for Distinguishing Hepatitis C Viruses with and without Liver Cancer-related Mutations in the Viral Core Gene.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00515.
    PubMed     Text format     Abstract available


  89. BERZIGOTTI A, Boyer TD, Castera L, de Franchis R, et al
    Reply to "Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno's VI consensus".
    J Hepatol. 2015 Jul 23. pii: S0168-8278(15)00475.
    PubMed     Text format    


  90. JEPSEN P, Watson H, Andersen PK, Vilstrup H, et al
    Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.
    J Hepatol. 2015 Jul 20. pii: S0168-8278(15)00470.
    PubMed     Text format     Abstract available


  91. PERAZZO H, Fernandes FF, Castro Filho EC, Perez RM, et al
    Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno's VI consensus.
    J Hepatol. 2015 Jul 20. pii: S0168-8278(15)00468.
    PubMed     Text format    


  92. YANG YH, Chen WC, Tsan YT, Chen MJ, et al
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2015 Jul 18. pii: S0168-8278(15)00469.
    PubMed     Text format     Abstract available


  93. BERNARDI M, Moreau R, Angeli P, Schnabl B, et al
    Mechanisms of Decompensation and Organ Failure in Cirrhosis: From Peripheral arterial Vasodilation to Systemic Inflammation Hypothesis.
    J Hepatol. 2015 Jul 17. pii: S0168-8278(15)00466.
    PubMed     Text format     Abstract available


    June 2015
  94. FERENCI P, Kozbial K, Mandorfer M, Hofer H, et al
    HCV targeting of patients with cirrhosis.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00393.
    PubMed     Text format     Abstract available


  95. LAMPERTICO P, Invernizzi F, Vigano M, Loglio A, et al
    The long-term benefits of nucleos(t)ide analogs on esophageal varices in compensated HBV cirrhotics with no or small esophageal varices: A 12-year prospective cohort study.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00397.
    PubMed     Text format     Abstract available


  96. ALEXOPOULOU A, Vasilieva L, Agiasotelli D, Dourakis SP, et al
    Fungal Infections in patients with cirrhosis.
    J Hepatol. 2015 Jun 18. pii: S0168-8278(15)00396.
    PubMed     Text format    


  97. COUDROY R, Jamet A, Thille AW
    Is skin mottling a predictor of high mortality in non-selected patients with cirrhosis admitted to intensive care unit?
    J Hepatol. 2015 Jun 5. pii: S0168-8278(15)00383.
    PubMed     Text format    


    May 2015
  98. YADA A, Iimuro Y, Uyama N, Uda Y, et al
    Splenectomy attenuates murine liver fibrosis with hypersplenism stimulating hepatic accumulation of Ly-6C macrophages.
    J Hepatol. 2015 May 25. pii: S0168-8278(15)00337.
    PubMed     Text format     Abstract available


  99. FARRAR CT, DePeralta DK, Day H, Rietz TA, et al
    3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model.
    J Hepatol. 2015 May 25. pii: S0168-8278(15)00335.
    PubMed     Text format     Abstract available


  100. DA SILVA MIOZZO SA, Tovo CV, John JA, de Mattos AA, et al
    Proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhosis: an undesirable association?
    J Hepatol. 2015 May 23. pii: S0168-8278(15)00334.
    PubMed     Text format    


  101. THEVENOT T, Monnet E, Di Martino V
    Reply to "Albumin infusion in cirrhotic patients with non-SBP infections: end of the story?"
    J Hepatol. 2015 May 18. pii: S0168-8278(15)00330.
    PubMed     Text format    


  102. MERLI M, Lucidi C, Lattanzi B, Riggio O, et al
    Albumin infusion in cirrhotic patients with infections other than Spontaneous Bacterial Peritonitis: end of the story?
    J Hepatol. 2015 May 16. pii: S0168-8278(15)00329.
    PubMed     Text format    


  103. MEHTA G, Dusheiko G
    Hepatitis C treatment and quality of life - you can't always get what you want, but you might get what you need.
    J Hepatol. 2015 May 13. pii: S0168-8278(15)00326.
    PubMed     Text format    


  104. ADAMS LA, Ratziu V
    Non-alcoholic fatty liver - perhaps not so benign.
    J Hepatol. 2015;62:1002-4.
    PubMed     Text format    


    April 2015
  105. MANNAERTS I, Leite SB, Verhulst S, Claerhout S, et al
    The Hippo pathway effector YAP controls mouse hepatic stellate cell activation.
    J Hepatol. 2015 Apr 20. pii: S0168-8278(15)00294.
    PubMed     Text format     Abstract available


  106. BARCENA C, Stefanovic M, Tutusaus A, Joannas L, et al
    Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.
    J Hepatol. 2015 Apr 20. pii: S0168-8278(15)00296.
    PubMed     Text format     Abstract available


  107. ELIA C, Graupera I, Barreto R, Sola E, et al
    Severe acute kidney injury associated with non-steroidal antiinflammatory drugs in cirrhosis: a case-control study.
    J Hepatol. 2015 Apr 11. pii: S0168-8278(15)00250.
    PubMed     Text format     Abstract available


  108. ARROYO V, Moreau R, Jalan R, Gines P, et al
    Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  109. BOURSIER J, de Ledinghen V, Poynard T, Guechot J, et al
    An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards.
    J Hepatol. 2015;62:807-15.
    PubMed     Text format     Abstract available


  110. TRAUTWEIN C, Friedman SL, Schuppan D, Pinzani M, et al
    Hepatic fibrosis: Concept to treatment.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


    March 2015
  111. MAJUMDAR A, Delatycki MB, Crowley P, Lokan J, et al
    An autosomal dominant form of non-cirrhotic portal hypertension.
    J Hepatol. 2015 Mar 18. pii: S0168-8278(15)00194.
    PubMed     Text format    


  112. LAURIDSEN MM, Bajaj JS
    Hepatic Encephalopathy Treatment and Driving: A Continental Divide.
    J Hepatol. 2015 Mar 18. pii: S0168-8278(15)00195.
    PubMed     Text format    


  113. YOUNOSSI ZM, Stepanova M, Afdhal N, Kowdley KV, et al
    Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
    J Hepatol. 2015 Mar 17. pii: S0168-8278(15)00192.
    PubMed     Text format     Abstract available


  114. WONG F, O'Leary JG, Reddy KR, Kamath PS, et al
    A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be.
    J Hepatol. 2015;62:741-3.
    PubMed     Text format    


  115. FAGUNDES C, Barreto R, Rodriguez E, Graupera I, et al
    Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be".
    J Hepatol. 2015;62:743-4.
    PubMed     Text format    


  116. PIANO S, Tonon M, Cavallin M, Morando F, et al
    Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be".
    J Hepatol. 2015;62:744-6.
    PubMed     Text format    


  117. MEIER RP, Mahou R, Morel P, Meyer J, et al
    Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice.
    J Hepatol. 2015;62:634-41.
    PubMed     Text format     Abstract available


  118. PAWLAK M, Lefebvre P, Staels B
    Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
    J Hepatol. 2015;62:720-33.
    PubMed     Text format     Abstract available


  119. ALTROCK E, Sens C, Wuerfel C, Vasel M, et al
    Inhibition of fibronectin deposition improves experimental liver fibrosis.
    J Hepatol. 2015;62:625-33.
    PubMed     Text format     Abstract available


    February 2015
  120. SIMON TG, King LY, Chung RT
    Coagulation and fibrosis: a potential non-negligible target of statins in chronic hepatitis.
    J Hepatol. 2015 Feb 26. pii: S0168-8278(15)00138.
    PubMed     Text format    


  121. BITTO N, Salerno F, Tripodi A, Mura V, et al
    Coagulation and fibrosis: a potential non-negligible target of statins in chronic hepatitis.
    J Hepatol. 2015 Feb 25. pii: S0168-8278(15)00137.
    PubMed     Text format    


  122. FORNER A, Vilana R, Sole M, Bruix J, et al
    Response to: Poor Contrast Enhanced Ultrasonography! There is no limit to its decline in the diagnosis of Hepatocellular Carcinoma on cirrhosis!
    J Hepatol. 2015 Feb 19. pii: S0168-8278(15)00123.
    PubMed     Text format    


  123. GIORGIO A, Giorgio V, Matteucci P
    Poor contrast enhanced ultrasonography! There is no limit to its sdecline in the diagnosis of hepatocellular carcinoma on cirrhosis!
    J Hepatol. 2015 Feb 19. pii: S0168-8278(15)00129.
    PubMed     Text format    


  124. SHI Y, Wu W, Yang Y, Yang Q, et al
    Decreased Tim-3 expression is associated with functional abnormalities of monocytes in de-compensated cirrhosis without overt bacterial infection.
    J Hepatol. 2015 Feb 18. pii: S0168-8278(15)00127.
    PubMed     Text format     Abstract available


  125. KOCABAYOGLU P, Lade A, Lee YA, Dragomir AC, et al
    beta-PDGF Receptor Expressed by Hepatic Stellate Cells Regulates Fibrosis in Murine Liver Injury, but Not Carcinogenesis.
    J Hepatol. 2015 Feb 9. pii: S0168-8278(15)00073.
    PubMed     Text format     Abstract available


  126. DEFFIEUX T, Gennisson JL, Bousquet L, Corouge M, et al
    Investigating liver stiffness and viscosity for fibrosis, steatosis and activity staging using shear wave elastography.
    J Hepatol. 2015;62:317-24.
    PubMed     Text format     Abstract available


    January 2015
  127. LI H, Xia Q, Zeng B, Li ST, et al
    Submassive hepatic necrosis distinguishes HBV-associated acute-on chronic liver failure from cirrhotic patients with acute decompensation.
    J Hepatol. 2015 Jan 31. pii: S0168-8278(15)00060.
    PubMed     Text format     Abstract available


  128. REHM J, Roerecke M
    Patterns of drinking and liver cirrhosis - what do we know and where do we go?
    J Hepatol. 2015 Jan 31. pii: S0168-8278(15)00058.
    PubMed     Text format    


  129. ALLARD MA, Sebagh M, Ruiz A, Guettier C, et al
    Does Pathological Response for Hepatocellular Carcinoma in Patients with Cirrhosis Predict Outcome after Liver Resection or Transplantation?
    J Hepatol. 2015 Jan 31. pii: S0168-8278(15)00054.
    PubMed     Text format     Abstract available


  130. GASKARI SA, Liu H, D'Mello C, Kunos G, et al
    Blunted Cardiac Response to Hemorrhage in Cirrhotic Rats is Mediated by Local Macrophage-Released Endocannabinoids.
    J Hepatol. 2015 Jan 29. pii: S0168-8278(15)00052.
    PubMed     Text format     Abstract available


  131. ANGELI P, Gines P, Wong F, Bernardi M, et al
    Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites.
    J Hepatol. 2015 Jan 27. pii: S0168-8278(14)00958.
    PubMed     Text format    


  132. ASKGAARD G, Gronbaek M, Kjaer MS, Tjonneland A, et al
    Alcohol drinking pattern and risk of alcoholic liver cirrhosis: A prospective cohort study.
    J Hepatol. 2015 Jan 20. pii: S0168-8278(14)00923.
    PubMed     Text format     Abstract available


  133. NEGRO F
    Are statins a remedy for all seasons?
    J Hepatol. 2015;62:8-10.
    PubMed     Text format    


  134. FORNER A, Vilana R, Bianchi L, Rodriguez-Lope C, et al
    Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm.
    J Hepatol. 2015;62:150-5.
    PubMed     Text format     Abstract available


  135. CUBERO FJ, Zhao G, Nevzorova YA, Hatting M, et al
    Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury.
    J Hepatol. 2015;62:140-9.
    PubMed     Text format     Abstract available


    December 2014
  136. FERNANDEZ J
    Prognostic Value of Skin Perfusion Alterations in Cirrhotic Patients with Septic Shock.
    J Hepatol. 2014 Dec 24. pii: S0168-8278(14)00952.
    PubMed     Text format    


  137. MORGAN TR
    Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding.
    J Hepatol. 2014 Dec 24. pii: S0168-8278(14)00942.
    PubMed     Text format    


  138. KLUGER MD, Salceda JA, Laurent A, Tayar C, et al
    Liver Resection For Hepatocellular Carcinoma in 313 Western Patients: Tumor Biology and Underlying Liver Rather than Tumor Size Drive Prognosis.
    J Hepatol. 2014 Dec 18. pii: S0168-8278(14)00939.
    PubMed     Text format     Abstract available


  139. MORRISON MC, Liang W, Mulder P, Verschuren L, et al
    Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE *3Leiden mice.
    J Hepatol. 2014 Dec 13. pii: S0168-8278(14)00929.
    PubMed     Text format     Abstract available


  140. TERG R, Casciato P, Garbe C, Cartier M, et al
    Proton Pump Inhibitor Therapy Does Not Increase the Incidence of Spontaneous Bacterial Peritonitis in Cirrhosis: A Multicenter Prospective Study.
    J Hepatol. 2014 Dec 3. pii: S0168-8278(14)00885.
    PubMed     Text format     Abstract available


    November 2014
  141. MCPHERSON S, Hardy T, Henderson E, Burt AD, et al
    Evidence of NAFLD Progression from Steatosis to Fibrosing-Steatohepatitis Using Paired Biopsies: Implications for Prognosis & Clinical Management.
    J Hepatol. 2014 Nov 29. pii: S0168-8278(14)00883.
    PubMed     Text format     Abstract available


  142. KIM GA, Lee HC, Kim MJ, Ha Y, et al
    Incidence of Hepatocellular Carcinoma after HBsAg Seroclearance in Chronic Hepatitis B Patients: a Need for Surveillance.
    J Hepatol. 2014 Nov 28. pii: S0168-8278(14)00880.
    PubMed     Text format     Abstract available


  143. JALAN R, Pavesi M, Saliba F, Amoros A, et al
    The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure.
    J Hepatol. 2014 Nov 22. pii: S0168-8278(14)00856.
    PubMed     Text format     Abstract available


  144. THEVENOT T, Bureau C, Oberti F, Anty R, et al
    Effect of Albumin in Cirrhotic Patients with Infection Other Than Spontaneous Bacterial Peritonitis. A Randomized Trial.
    J Hepatol. 2014 Nov 21. pii: S0168-8278(14)00862.
    PubMed     Text format     Abstract available


  145. KESSLER SM, Barghash A, Laggai S, Helms V, et al
    Hepatic hepcidin expression is decreased in cirrhosis and HCC.
    J Hepatol. 2014 Nov 21. pii: S0168-8278(14)00861.
    PubMed     Text format    


  146. LUNOVA M, Nahon P, Trautwein C, Strnad P, et al
    Hepcidin in chronic liver disease and hepatocellular carcinoma: the plot thickens.
    J Hepatol. 2014 Nov 21. pii: S0168-8278(14)00851.
    PubMed     Text format    


  147. SOMBETZKI M, Fuchs CD, Fickert P, Oesterreicher C, et al
    24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
    J Hepatol. 2014 Nov 21. pii: S0168-8278(14)00865.
    PubMed     Text format     Abstract available


  148. MAIWALL R, Maras JS, Kumar S, Sarin SK, et al
    Serum Ferritin in decompensated cirrhosis: Marker of both iron excess and inflammation!
    J Hepatol. 2014 Nov 11. pii: S0168-8278(14)00819.
    PubMed     Text format    


  149. RUDLER M, Mouri S, Charlotte F, Lebray P, et al
    Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding.
    J Hepatol. 2014 Nov 11. pii: S0168-8278(14)00818.
    PubMed     Text format     Abstract available


  150. RYAN JD, Chin JL, Crowe J
    Ferritin in decompensated cirrhosis: iron or inflammation?
    J Hepatol. 2014 Nov 7. pii: S0168-8278(14)00814.
    PubMed     Text format    


  151. GAMBATO M, Lens S, Navasa M, Forns X, et al
    Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
    J Hepatol. 2014;61.
    PubMed     Text format     Abstract available


  152. WESTBROOK RH, Dusheiko G
    Natural history of hepatitis C.
    J Hepatol. 2014;61.
    PubMed     Text format     Abstract available


    October 2014
  153. PAGE A, Paoli PP, Hill SJ, Howarth R, et al
    Alcohol Directly Stimulates Epigenetic Modifications in Hepatic Stellate Cells.
    J Hepatol. 2014 Oct 20. pii: S0168-8278(14)00735.
    PubMed     Text format     Abstract available


  154. HUANG CF, Dai CY, Yeh ML, Huang CI, et al
    Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection.
    J Hepatol. 2014 Oct 20. pii: S0168-8278(14)00740.
    PubMed     Text format     Abstract available


  155. GUO R, Xu X, Babcock SA, Zhang Y, et al
    Aldehyde Dehydrogenase-2 (ALDH2) Ameliorates Chronic Alcohol Ingestion-Induced Hepatic Steatosis and Inflammation: Role of Autophagy.
    J Hepatol. 2014 Oct 20. pii: S0168-8278(14)00738.
    PubMed     Text format     Abstract available


  156. GALBOIS A, Bige N, Pichereau C, Boelle PY, et al
    Exploration of skin perfusion in cirrhotic patients with septic shock.
    J Hepatol. 2014 Oct 19. pii: S0168-8278(14)00741.
    PubMed     Text format     Abstract available


  157. BERRES ML, Asmacher S, Lehmann J, Jansen C, et al
    CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    J Hepatol. 2014 Oct 17. pii: S0168-8278(14)00734.
    PubMed     Text format     Abstract available


  158. SECKLEHNER J, Richardson CA
    The reporting of animal welfare details in liver research: A review of studies describing bile duct ligation in mice (2011-2013).
    J Hepatol. 2014 Oct 1. pii: S0168-8278(14)00720.
    PubMed     Text format    


    September 2014
  159. LANGHANS B, Alwan AW, Kramer B, Glassner A, et al
    Regulatory CD4 T cells (Tregs) Modulate the Interaction between NK Cells and Hepatic Stellate Cells (HSC) by Acting on either Cell Type.
    J Hepatol. 2014 Sep 4. pii: S0168-8278(14)00626.
    PubMed     Text format     Abstract available


  160. SHOUVAL D, Friedman SL
    Focusing on the Past, Present and Future of Hepatology.
    J Hepatol. 2014 Sep 4. pii: S0168-8278(14)00627.
    PubMed     Text format    


    August 2014
  161. SIMON TG, King LY, Zheng H, Chung RT, et al
    Statin Use is Associated with a Reduced Risk of Fibrosis Progression in Chronic Hepatitis C.
    J Hepatol. 2014 Aug 15. pii: S0168-8278(14)00552.
    PubMed     Text format     Abstract available


  162. CHEN L, Li J, Zhang J, Dai C, et al
    S100A4 promotes liver fibrosis via activation of hepatic stellate cells.
    J Hepatol. 2014 Aug 8. pii: S0168-8278(14)00541.
    PubMed     Text format     Abstract available


  163. TIAN W, Hao C, Fan Z, Weng X, et al
    Myocardin related transcription factor A programs epigenetic activation of hepatic stellate cells.
    J Hepatol. 2014 Aug 7. pii: S0168-8278(14)00533.
    PubMed     Text format     Abstract available


    July 2014
  164. POYNARD T, Vergniol J, Ngo Y, Foucher J, et al
    Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest) and elastography (FibroScan).
    J Hepatol. 2014 Jul 9. pii: S0168-8278(14)00457.
    PubMed     Text format     Abstract available


  165. ZHANG L, Schuppan D
    Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype.
    J Hepatol. 2014;61:166-8.
    PubMed     Text format    


  166. TRIPODI A, Fracanzani AL, Primignani M, Chantarangkul V, et al
    Procoagulant imbalance in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2014;61:148-54.
    PubMed     Text format     Abstract available


  167. HUANG Y, de Boer WB, Adams LA, MacQuillan G, et al
    Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome.
    J Hepatol. 2014;61:22-7.
    PubMed     Text format     Abstract available


  168. CHIAVAROLI L, Ha V, Kendall CW, Sievenpiper JL, et al
    Is industrial fructose just a marker of an unhealthy dietary pattern?
    J Hepatol. 2014;61:172-3.
    PubMed     Text format    


  169. PETTA S, Marchesini G, Craxi A
    Reply to: "is industrial fructose just a marker of an unhealthy dietary pattern?".
    J Hepatol. 2014;61:173-5.
    PubMed     Text format    


    June 2014
  170. NISCHALKE HD, Lutz P, Kramer B, Sohne J, et al
    A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease.
    J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00401.
    PubMed     Text format     Abstract available


  171. COLOMBO M, Strasser SI, Moreno C, Ferreira PA, et al
    Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program.
    J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400.
    PubMed     Text format     Abstract available


  172. YANG JW, Hien TT, Lim SC, Jun DW, et al
    Pin1 induction in the fibrotic liver and its roles in TGF-beta1 expression and Smad2/3 phosphorylation.
    J Hepatol. 2014;60:1235-41.
    PubMed     Text format     Abstract available


    May 2014
  173. PINYOL R, Tovar V, Llovet JM
    TERT promoter mutations: Gatekeeper and driver of hepatocellular carcinoma.
    J Hepatol. 2014 May 22. pii: S0168-8278(14)00375.
    PubMed     Text format    


  174. KROY DC, Schumacher F, Ramadori P, Hatting M, et al
    Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic-steatohepatitis in mice.
    J Hepatol. 2014 May 15. pii: S0168-8278(14)00360.
    PubMed     Text format     Abstract available


  175. HARRIS RJ, Thomas B, Griffiths J, Costella A, et al
    Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.
    J Hepatol. 2014 May 10. pii: S0168-8278(14)00318.
    PubMed     Text format     Abstract available


  176. NI HM, Woolbright BL, Williams J, Copple B, et al
    Nrf2 Promotes the Development of Fibrosis and Tumorigenesis in Mice with Defective Hepatic Autophagy.
    J Hepatol. 2014 May 7. pii: S0168-8278(14)00306.
    PubMed     Text format     Abstract available


  177. MACALUSO FS, Maida M, Camma C, Cabibbo G, et al
    Steatosis Affects the Performance of Liver Stiffness Measurement for Fibrosis Assessment in Patients with Genotype 1 Chronic Hepatitis C.
    J Hepatol. 2014 May 7. pii: S0168-8278(14)00308.
    PubMed     Text format     Abstract available


  178. FRIEDMAN SL
    Replacing a crystal ball with a calculator in predicting liver disease outcomes.
    J Hepatol. 2014;60:905-6.
    PubMed     Text format    


  179. MCPHERSON S, Henderson E, Burt AD, Day CP, et al
    Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2014;60:1055-62.
    PubMed     Text format     Abstract available


  180. TACKE F, Zimmermann HW
    Macrophage heterogeneity in liver injury and fibrosis.
    J Hepatol. 2014;60:1090-6.
    PubMed     Text format     Abstract available


  181. ASRANI SK, Talwalkar JA, Kamath PS, Shah VH, et al
    Role of magnetic resonance elastography in compensated and decompensated liver disease.
    J Hepatol. 2014;60:934-9.
    PubMed     Text format     Abstract available


    April 2014
  182. MAAN R, van der Meer AJ, Hansen BE, Feld JJ, et al
    Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.
    J Hepatol. 2014 Apr 26. pii: S0168-8278(14)00284.
    PubMed     Text format     Abstract available


  183. HEZODE C, Fontaine H, Barthe Y, Carrat F, et al
    Reply to: "From the CUPIC study: great times are not coming(?)".
    J Hepatol. 2014;60:900-1.
    PubMed     Text format    


  184. SCHMIDT-MARTIN D, Houlihan D, McCormick A
    From the CUPIC study: great times are not coming(?).
    J Hepatol. 2014;60:899-900.
    PubMed     Text format    


  185. SHAH HA, Azam Z, Rauf J, Abid S, et al
    Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial.
    J Hepatol. 2014;60:757-64.
    PubMed     Text format     Abstract available


  186. MARINO Z, Mensa L, Crespo G, Miquel R, et al
    Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation.
    J Hepatol. 2014 Apr 1. pii: S0168-8278(14)00210.
    PubMed     Text format     Abstract available


    March 2014
  187. TOMITA K, Teratani T, Suzuki T, Shimizu M, et al
    Acyl-CoA:cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells.
    J Hepatol. 2014 Mar 18. pii: S0168-8278(14)00164.
    PubMed     Text format     Abstract available


  188. DEUFFIC-BURBAN S, Schwarzinger M, Obach D, Mallet V, et al
    Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188).
    J Hepatol. 2014 Mar 17. pii: S0168-8278(14)00155.
    PubMed     Text format     Abstract available


  189. LEROY V, Sturm N, Faure P, Trocme C, et al
    Prospective evaluation of Fibrotest, Fibrometer and Hepascore for staging liver fibrosis in chronic hepatitis B: Comparison with hepatitis C.
    J Hepatol. 2014 Mar 11. pii: S0168-8278(14)00137.
    PubMed     Text format     Abstract available


  190. SOLA E, Fagundes C, Barreto R, Elia C, et al
    Reply to: "To close the stable door before the horse has bolted".
    J Hepatol. 2014;60:679-80.
    PubMed     Text format    


  191. THALHEIMER U, Burroughs AK
    To close the stable door before the horse has bolted.
    J Hepatol. 2014;60:678-9.
    PubMed     Text format    


  192. PIANO S, Morando F, Angeli P
    Reply to: "To close the stable door before the horse has bolted".
    J Hepatol. 2014;60:680-1.
    PubMed     Text format    


    February 2014
  193. NISHIKAWA T, Bellance N, Damm A, Bing H, et al
    A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease.
    J Hepatol. 2014 Feb 25. pii: S0168-8278(14)00120.
    PubMed     Text format     Abstract available


  194. XU S, Wang Y, Tai DC, Wang S, et al
    qFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients.
    J Hepatol. 2014 Feb 25. pii: S0168-8278(14)00121.
    PubMed     Text format     Abstract available


  195. WANG L, Hartmann P, Haimerl M, Bathena SP, et al
    Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids.
    J Hepatol. 2014 Feb 19. pii: S0168-8278(14)00118.
    PubMed     Text format     Abstract available


  196. TOMITA H, Masugi Y, Hoshino K, Fuchimoto Y, et al
    Long-term Native Liver Fibrosis in Biliary Atresia: Development of a Novel Scoring System Using Histology and Standard Liver Tests.
    J Hepatol. 2014 Feb 15. pii: S0168-8278(14)00104.
    PubMed     Text format     Abstract available


  197. CARPINO G, Cardinale V, Gentile R, Onori P, et al
    Evidence for multipotent endodermal stem/progenitor cell populations in human gallbladder.
    J Hepatol. 2014 Feb 12. pii: S0168-8278(14)00102.
    PubMed     Text format     Abstract available


  198. VITALE A, Cucchetti A, Qiao GL, Cescon M, et al
    Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit.
    J Hepatol. 2014 Feb 6. pii: S0168-8278(14)00094.
    PubMed     Text format     Abstract available


  199. INNES H, Goldberg D, Dusheiko G, Hayes P, et al
    Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model.
    J Hepatol. 2014 Feb 5. pii: S0168-8278(14)00066.
    PubMed     Text format     Abstract available


    January 2014
  200. MANINI MA, Sangiovanni A, Fornari F, Piscaglia F, et al
    Clinical and Economical Impact of 2010 AASLD Guidelines for the Diagnosis of Hepatocellular Carcinoma.
    J Hepatol. 2014 Jan 21. pii: S0168-8278(14)00049.
    PubMed     Text format     Abstract available


    December 2013
  201. FAGIUOLI S, Colli A, Bruno R, Craxi A, et al
    Management of infections pre- and post-liver transplantation: Report of a AISF Consensus Conference.
    J Hepatol. 2013 Dec 30. pii: S0168-8278(13)00890.
    PubMed     Text format     Abstract available


    November 2013
  202. POYNARD T, Vergniol J, Ngo Y, Foucher J, et al
    Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest) and transient elastography (FibroScan).
    J Hepatol. 2013 Nov 26. pii: S0168-8278(13)00817.
    PubMed     Text format     Abstract available


  203. SHOEB D, Dearden J, Weatherall A, Bargery C, et al
    Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
    J Hepatol. 2013 Nov 26. pii: S0168-8278(13)00812.
    PubMed     Text format     Abstract available


  204. AUGUSTIN S , Millan L, Gonzalez A, Martell M, et al
    Detection of Early Portal Hypertension with Routine Data and Liver Stiffness In Patients with Asymptomatic Liver Disease: A Prospective Study.
    J Hepatol. 2013 Nov 5. pii: S0168-8278(13)00753.
    PubMed     Text format     Abstract available


    October 2013
  205. PETTA S, Marchesini G, Craxi A
    Reply to: "Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients"
    J Hepatol. 2013 Oct 25. pii: S0168-8278(13)00743.
    PubMed     Text format    


  206. KITSON MT, Murnane L, Kemp W, Roberts SK, et al
    Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients.
    J Hepatol. 2013 Oct 25. pii: S0168-8278(13)00738.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: